---
figid: PMC9111035__PTR-36-2394-g004
figtitle: Critical evaluation of risk to reward ratio of quercetin supplementation
  for COVID‐19 and associated comorbid conditions
organisms:
- Nicotiana tabacum
- herbal medicine
- Helianthus annuus
- Allium cepa
- Ginkgo biloba
- Komagataella pastoris
- Symphonia globulifera
- Torreya nucifera
- Broussonetia papyrifera
- Adolphia infesta
- Polygonum aviculare
- Caesalpinia pulcherrima
- Myrsine melanophloeos
- Severe acute respiratory syndrome coronavirus 2
- Adenoviridae
- Coronaviridae
- Severe acute respiratory syndrome-related coronavirus
- Middle East respiratory syndrome-related coronavirus
- Respiratory syncytial virus
- Orthomyxoviridae
- Betacoronavirus
- Enterovirus
- Mus musculus
- Rattus norvegicus
- Cavia porcellus
- Homo sapiens
- Sus scrofa
- Opsanus beta
pmcid: PMC9111035
filename: PTR-36-2394-g004.jpg
figlink: /pmc/articles/PMC9111035/figure/ptr7461-fig-0004/
number: F4
caption: Anti‐adipogenesis activity of quercetin. Quercetin exerts a suppressive effect
  on fat accumulation by activating HSL which converts TGs to FFAs. Moreover, it also
  stimulates the expression of UCP1 to increase energy expenditure, an important player
  in the anti‐obesity phenomenon. Furthermore, quercetin also restricts pre‐adipocyte
  differentiation, adipogenesis, and inflammation by inhibiting MAPK mediated signaling
  and its downstream factors like PPARγ and CREB. Quercetin opposes the anti‐apoptotic
  effect of ERK1/2 signaling to promote apoptosis in mature adipocytes and thereby
  displays its anti‐obesity potential. Furthermore, quercetin also increases cholesterol
  efflux from macrophages to prevent foam cell formation via activation of the PPARγ‐ABCA1
  pathway and thereby lowers the risk of atherosclerosis. ABCA1, ATP‐binding cassette
  transporter A1; AC, adenylyl cyclase; Bcl‐2, B‐cell lymphoma 2; cAMP, cyclic adenosine
  monophosphate; CREB, CCAAT/enhancer‐binding protein; DG, diglycerides; ERK, extracellular‐signal‐regulated
  kinase; FFAs, free fatty acids; HSL, hormone‐sensitive lipase; IR, insulin receptor;
  LEP‐R, leptin receptor; MAPK, mitogen‐activated protein kinase; MEK, ERK kinase;
  MG, monoglycerides; PGC1 α, peroxisome proliferator‐activated receptor gamma coactivator
  1‐α; PKA, protein kinase A; PPARγ, peroxisome proliferator‐activated receptor γ;
  TGs, triglycerides; UCP1, uncoupling protein 1
papertitle: A critical evaluation of risk to reward ratio of quercetin supplementation
  for COVID‐19 and associated comorbid conditions.
reftext: Anil Pawar, et al. Phytother Res. 2022 Apr 8 ;36(6):2394-2415.
year: '2022'
doi: 10.1002/ptr.7461
journal_title: Phytotherapy Research
journal_nlm_ta: Phytother Res
publisher_name: John Wiley & Sons, Ltd.
keywords: chronic obstructive pulmonary disease | coagulation | COVID‐19 | diabetes
  | hypertension | quercetin
automl_pathway: 0.9600055
figid_alias: PMC9111035__F4
figtype: Figure
organisms_ner:
- Mus musculus
- Sus scrofa
- Homo sapiens
- Rattus norvegicus
- Cavia porcellus
redirect_from: /figures/PMC9111035__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9111035__PTR-36-2394-g004.html
  '@type': Dataset
  description: Anti‐adipogenesis activity of quercetin. Quercetin exerts a suppressive
    effect on fat accumulation by activating HSL which converts TGs to FFAs. Moreover,
    it also stimulates the expression of UCP1 to increase energy expenditure, an important
    player in the anti‐obesity phenomenon. Furthermore, quercetin also restricts pre‐adipocyte
    differentiation, adipogenesis, and inflammation by inhibiting MAPK mediated signaling
    and its downstream factors like PPARγ and CREB. Quercetin opposes the anti‐apoptotic
    effect of ERK1/2 signaling to promote apoptosis in mature adipocytes and thereby
    displays its anti‐obesity potential. Furthermore, quercetin also increases cholesterol
    efflux from macrophages to prevent foam cell formation via activation of the PPARγ‐ABCA1
    pathway and thereby lowers the risk of atherosclerosis. ABCA1, ATP‐binding cassette
    transporter A1; AC, adenylyl cyclase; Bcl‐2, B‐cell lymphoma 2; cAMP, cyclic adenosine
    monophosphate; CREB, CCAAT/enhancer‐binding protein; DG, diglycerides; ERK, extracellular‐signal‐regulated
    kinase; FFAs, free fatty acids; HSL, hormone‐sensitive lipase; IR, insulin receptor;
    LEP‐R, leptin receptor; MAPK, mitogen‐activated protein kinase; MEK, ERK kinase;
    MG, monoglycerides; PGC1 α, peroxisome proliferator‐activated receptor gamma coactivator
    1‐α; PKA, protein kinase A; PPARγ, peroxisome proliferator‐activated receptor
    γ; TGs, triglycerides; UCP1, uncoupling protein 1
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mdk
  - Mapk3
  - Mapk1
  - Abca1
  - Trp53
  - Nfkb1
  - ac
  - Lipe
  - Ppargc1a
  - Ucp1
  - Tg
  - MAPK3
  - MAPK1
  - ABCA1
  - TP53
  - PRKACA
  - LIPE
  - PRKAA1
  - PPARGC1A
  - UCP1
  - TG
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - TP63
  - TP73
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - NFKB1
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACB
  - PRKACG
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - Tp53
  - Prkaa2
---
